GANX News and Press, Gain Therapeutics Inc. From 06/14/24

A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 1.8% to $131.88 on volume of 307,014,213 shares SRIVARU Holding Limited (SVMH) rose 49.2% to $0.2275 on volume of 274,465,266 shares Nauticus Robotics Inc. (KITT) rose 19.6% to $0.192 on volume of 161,46...

A look at the top 10 most actives in the United States SRIVARU Holding Limited (SVMH) rose 94.8% to $0.2971 on volume of 77,516,058 shares NVIDIA Corporation (NVDA) fell 0.3% to $129.16 on volume of 39,120,242 shares Longeveron Inc. (LGVN) rose 27.0% to $3.415 on volume of 36,214,736 shar...

2024-06-14 04:35:45 ET More on Gain Therapeutics Gain Therapeutics: Phase 1 Readout Awaits For Parkinson's Drug With Great Potential Gain Therapeutics shares fall on proposed public offering Seeking Alpha’s Quant Rating on Gain Therapeutics Historical ...

BETHESDA, Md., June 13, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced the pricing of an underwritten public offering of (i) 7,116,547 shares of its common stock at a public offering price of $1.35 per sha...

2024-06-13 16:56:00 ET More on Gain Therapeutics Gain Therapeutics: Phase 1 Readout Awaits For Parkinson's Drug With Great Potential Seeking Alpha’s Quant Rating on Gain Therapeutics Historical earnings data for Gain Therapeutics Financial information ...

2024-05-30 10:01:19 ET More on Health Care Select Sector SPDR XLV: Healthcare Is Ripe For Buying, Despite Patent Cliff XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care Short interest in S&P 500 ...

BETHESDA, Md., May 30, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announce...

2024-05-29 18:15:11 ET Summary Gain Therapeutics, Inc.'s drug candidate GT-02287 has best-in-class potential to slow or stop disease progression in Parkinson's disease. Gain is progressing at an impressive speed through its Phase 1 trial. Drug discovery engine Magellan, which ...

2024-05-14 13:54:40 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Gain Therapeutics (NASDAQ: GANX ) just reported results for the first quarter of 2024. Gain Therapeutics reported earnings per share of -22 cents. This was above the analy...

2024-05-14 09:12:37 ET More on Gain Therapeutics Seeking Alpha’s Quant Rating on Gain Therapeutics Historical earnings data for Gain Therapeutics Financial information for Gain Therapeutics Read the full article on Seeking Alpha For further det...